DJ
Therapeutic Areas
PMV Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PC14586 (revetrectinib) | Advanced solid tumors with p53 Y220C mutation | Phase 1/2 |
Leadership Team at PMV Pharmaceuticals
DM
David Mack, Ph.D.
Co-founder, President and Chief Executive Officer
WK
Winston Kung
Chief Financial Officer
KM
Kathleen Mahoney, M.D.
Chief Medical Officer
AL
Arnold Levine, Ph.D.
Co-founder and Chair of Scientific Advisory Board
AG
Andreas G. Bader, Ph.D.
Chief Scientific Officer
CP
Carol Prives, Ph.D.
Scientific Advisory Board Member
AF
Alan Fersht, Ph.D.
Scientific Advisory Board Member